España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan ire healthcare limited - ibuprofeno - suspensiÓn oral - 20 mg/ml - ibuprofeno 20 mg - ibuprofeno

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bgp products operations s.l. - betahistina dihidrocloruro - comprimido - 16 mg - betahistina dihidrocloruro 16 mg - betahistina

Unión Europea - español - EMA (European Medicines Agency)

taw pharma (ireland) limited - clorhidrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bgp products operations, s.l. - ibuprofeno - excipientes: hidrogeno carbonato de sodio,sacarina sodica,sacarosa,laurilsulfato de sodio,carbonato de sodio anhidro,croscarmelosa sodica - productos antiinflamatorios y antirreumÁticos no esteroideos - derivados del ácido propiónico - ibuprofeno

Unión Europea - español - EMA (European Medicines Agency)

viatris limited - besilato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agentes antitrombóticos - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). elevación del segmento st infarto agudo de miocardio, en combinación con aas en los pacientes tratados médicamente elegibles para la terapia trombolítica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. para más información, por favor refiérase a la sección 5.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bgp products operations, s.l. - ibuprofeno - excipientes: sacarina sodica,sacarosa,laurilsulfato de sodio,hidrogenocarbonato de sodio,carbonato sodico,croscarmelosa sodica - productos antiinflamatorios y antirreumÁticos no esteroideos - derivados del ácido propiónico - ibuprofeno

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bgp products operations s.l. - claritromicina - granulado para suspensiÓn oral - 25 mg/ml - claritromicina 25 mg - claritromicina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bgp products operations s.l. - claritromicina - granulado para suspensiÓn oral - 50 mg/ml - claritromicina 50 mg - claritromicina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

bgp products operations, s.l. - lipasa, proteasa, amilasa - excipientes: capsulas de gelatina dura,cetilico, alcohol - digestivos, incluyendo enzimas - preparados enzimáticos - multienzimas (lipasa, proteasa, etc.)